Pfizer, MicuRx and Cumencor to ally on tuberculosis research

9 April 2010 00:00 in Pharmaceutical Company Product News


Pfizer has entered into a new research and development alliance with MicuRx Pharmaceuticals and Cumencor Pharmaceuticals to create new treatments for tuberculosis.

The firm is allying with the two China-based health care companies in order to discover and commercialise therapies for multi-drug resistant strains of the respiratory ailment.

This research will take place at the ZhangJiang High-Tech Park in Shanghai, China using MicuRx's proprietary technology, with Pfizer providing funding for the ongoing work.

Pfizer has expressed confidence that any treatments developed under this collaboration will complement its existing portfolio of anti-infective agents.

Dr Zhengyu Yuan, president and chief executive officer of MicuRx, added: "We believe that it is critical to pursue development of new therapeutic options for patients suffering from this devastating disease around the world."

Earlier this week, it was announced that Pfizer will collaborate with biotechnology company MDRNA to develop treatments for a number of clinical targets based on RNA interference technology.

Other news stories from 09/04/2010

• GlaxoSmithKline and Crucell to develop malaria vaccine
• Pfizer, MicuRx and Cumencor to ally on tuberculosis research
• Bristol-Myers Squibb appoints new chief financial officer
• Takeda pledges support for British amputee football team
• Life Technologies to acquire Geneart
• Roche Diagnostics supplies NHS trust with clinical analyser
• NPA announces resignation of chief executive
• PracticeWorks acquires software provider Windent
• Checks on foreign doctors 'might have saved lives'
• Genzyme wins recommendation for Mozobil use by NHS Wales
• Biotronik receives European approval for new pacemaker
• Owen Mumford appoints new global head of quality

Related news

• Pfizer and Newcastle Hospitals Trust to ally on clinical research
• Pfizer launches online Viagra sales to combat counterfeiting
• Pfizer launches annual operational review
• Pfizer and BIND Therapeutics agree global collaboration
• Pfizer and Philadelphia hospital ally on paediatric research

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency

Feedback | News Archive | Browse News | Hotels | Links | Browse Jobs | Legal Notice | Privacy Policy

© Copyright 2013 Zenopa Ltd